206 related articles for article (PubMed ID: 8467609)
1. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.
Röther E; Lang B; Coldewey R; Hartung K; Peter HH
Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
Senaldi G; Makinde VA; Vergani D; Isenberg DA
Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
Kao AH; Navratil JS; Ruffing MJ; Liu CC; Hawkins D; McKinnon KM; Danchenko N; Ahearn JM; Manzi S
Arthritis Rheum; 2010 Mar; 62(3):837-44. PubMed ID: 20187154
[TBL] [Abstract][Full Text] [Related]
5. Serum complement abnormalities in the antinuclear antibody-positive relatives of children with systemic lupus erythematosus.
Lehman TJ; Hanson V; Singsen BH; Kornreich HK; Bernstein B; King KK
Arthritis Rheum; 1979 Sep; 22(9):954-8. PubMed ID: 314291
[TBL] [Abstract][Full Text] [Related]
6. Correlation between the levels of antinuclear antibodies, anti-DNA antibodies, and complement in systemic lupus erythematosus.
Nguyen CP; Cao VV; Fehér J; Gergely P
Acta Med Hung; 1988; 45(2):145-59. PubMed ID: 3266790
[TBL] [Abstract][Full Text] [Related]
7. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
8. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
Lim KL; Jones AC; Brown NS; Powell RJ
Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
[TBL] [Abstract][Full Text] [Related]
9. Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythematosus and the antiphospholipid syndrome.
Hammond A; Rudge AC; Loizou S; Bowcock SJ; Walport MJ
Arthritis Rheum; 1989 Mar; 32(3):259-64. PubMed ID: 2522783
[TBL] [Abstract][Full Text] [Related]
10. The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.
Morrow WJ; Williams DJ; Ferec C; Casburn-Budd R; Isenberg DA; Paice E; Snaith ML; Youinou P; Le Goff P
Ann Rheum Dis; 1983 Dec; 42(6):668-71. PubMed ID: 6606402
[TBL] [Abstract][Full Text] [Related]
11. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity.
Kerr LD; Adelsberg BR; Schulman P; Spiera H
Arthritis Rheum; 1989 Nov; 32(11):1406-13. PubMed ID: 2818657
[TBL] [Abstract][Full Text] [Related]
12. Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus.
Miyawaki Y; Sada K; Asano Y; Hayashi K; Yamamura Y; Hiramatsu S; Ohashi K; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
Lupus; 2018 Nov; 27(13):2093-2100. PubMed ID: 30309286
[TBL] [Abstract][Full Text] [Related]
13. [Complement system in disseminated lupus erythematosus].
Vasquez JJ; Fontan G; Gil A; Barbado J; Alvarez I; Ojeda JA
Rev Rhum Mal Osteoartic; 1977 Dec; 44(12):725-31. PubMed ID: 76330
[TBL] [Abstract][Full Text] [Related]
14. Complement activation in systemic lupus erythematosus: a marker of inflammation.
Kerr LD; Adelsberg BR; Spiera H
J Rheumatol; 1986 Apr; 13(2):313-9. PubMed ID: 3487647
[TBL] [Abstract][Full Text] [Related]
15. Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus.
Davis P; Cumming RH; Verrier-Jones J
Clin Exp Immunol; 1977 May; 28(2):226-32. PubMed ID: 301447
[TBL] [Abstract][Full Text] [Related]
16. The value of complement measurements in the assessment of lupus activity.
Milis L; Timmermans V; Morris CA; Pussell BA; Charlesworth JA
Aust N Z J Med; 1992 Aug; 22(4):338-44. PubMed ID: 1445021
[TBL] [Abstract][Full Text] [Related]
17. Urinary C3d is elevated in patients with active Lupus nephritis and a fall in its level after 3 months predicts response at 6 months on follow up.
Ganguly S; Majumder S; Kumar S; Gupta R; Muhammed H; Shobha V; Aggarwal A; Misra R
Lupus; 2020 Nov; 29(13):1800-1806. PubMed ID: 32807020
[TBL] [Abstract][Full Text] [Related]
18. Complement degradation product C3d in urine: marker of lupus nephritis.
Negi VS; Aggarwal A; Dayal R; Naik S; Misra R
J Rheumatol; 2000 Feb; 27(2):380-3. PubMed ID: 10685801
[TBL] [Abstract][Full Text] [Related]
19. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.
Charlesworth JA; Peake PW; Golding J; Mackie JD; Pussell BA; Timmermans V; Wakefield D
Ann Rheum Dis; 1989 Feb; 48(2):153-9. PubMed ID: 2784659
[TBL] [Abstract][Full Text] [Related]
20. Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients.
Saisoong S; Eiam-Ong S; Hanvivatvong O
Clin Exp Rheumatol; 2006; 24(1):51-8. PubMed ID: 16539819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
